-
Innovation Ranking
NewInnovation Ranking – ImmunoGen Inc
ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGen incorporates its proprietary...
-
Product Insights
NewNet Present Value Model: ImmunoGen Inc’s Pivekimab sunirine
Empower your strategies with our Net Present Value Model: ImmunoGen Inc's Pivekimab sunirine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: ImmunoGen Inc’s Izeltabart tapatansine
Empower your strategies with our Net Present Value Model: ImmunoGen Inc's Izeltabart tapatansine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.Drug Operating Profit Model
-
Company Insights
Innovation and Patenting activity of ImmunoGen Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ImmunoGen Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PVX-410 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PVX-410 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVX-410 in Multiple Myeloma (Kahler Disease) Drug Details: PVX-410 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PVX-410 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PVX-410 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVX-410 in Triple-Negative Breast Cancer (TNBC) Drug Details: PVX-410 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Multiple Myeloma (Kahler Disease) Drug Details: Galinpepimut-S is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Peritoneal Cancer Drug Details: Galinpepimut-S is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Small-Cell Lung Cancer Drug Details: Galinpepimut-S is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Fallopian Tube Cancer Drug Details: Galinpepimut-S is under...